menu
    • menu
    [{"orgOrder":0,"company":"Alivexis","sponsor":"Melodia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"MDI-0151","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Alivexis","amount2":0.28000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Alivexis \/ Melodia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Alivexis \/ Melodia Therapeutics"},{"orgOrder":0,"company":"Alivexis","sponsor":"Green Coinvest Investment Limited","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series C Financing","leadProduct":"MOD-A","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Alivexis","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Alivexis \/ Green Coinvest Investment Limited","highestDevelopmentStatusID":"3","companyTruncated":"Alivexis \/ Green Coinvest Investment Limited"},{"orgOrder":0,"company":"Alivexis","sponsor":"SBI Investment Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Alivexis","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Alivexis \/ SBI Investment Co","highestDevelopmentStatusID":"2","companyTruncated":"Alivexis \/ SBI Investment Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Alivexis

    Menu

    Alivexis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alivexis

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Alivexis

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MDI-0151

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Melodia Therapeutics

                            Deal Size : $275.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Melodia and Alivexis Sign Exclusive License for Cathepsin C Inhibitor

                            Details : Under the terms of the agreement, Alivexis grants Melodia worldwide rights to develop, manufacture, and commercialize MDI-0151 for the treatment of inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 21, 2024

                            Lead Product(s) : MDI-0151

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Melodia Therapeutics

                            Deal Size : $275.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alivexis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alivexis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MOD-A

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Green Coinvest Investment Limited

                            Deal Size : $20.4 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Modulus Discovery Closes $20.4M USD Series C

                            Details : Modulus will use the proceeds to further its portfolio of R&D programs driven by its proprietary computational drug discovery platform and globally networked operational model including lead asset MOD-A.

                            Product Name : MOD-A

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 01, 2022

                            Lead Product(s) : MOD-A

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Green Coinvest Investment Limited

                            Deal Size : $20.4 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alivexis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Alivexis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : SBI Investment Co

                            Deal Size : $25.5 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Modulus Discovery Closes $25.5M USD Series B

                            Details : Modulus will use the proceeds to further its unique small-molecule lead programs in oncology and inflammatory / immune disorders and expand its portfolio of early programs and collaborations including those with its strategic partner, PeptiDream, Inc.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 13, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : SBI Investment Co

                            Deal Size : $25.5 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth